Patient-reported outcomes (PROs) from DESTINY-Breast03, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC)
Curigliano G, Dunton K, Rosenlund M, Janek M, Cathcart J, Liu Y, Fasching P, Iwata H (2022)
Publication Type: Conference contribution
Publication year: 2022
Journal
Publisher: ELSEVIER
City/Town: AMSTERDAM
Pages Range: S196-S197
Conference Proceedings Title: ANNALS OF ONCOLOGY
DOI: 10.1016/j.annonc.2022.03.182
Authors with CRIS profile
Involved external institutions
Daiichi Sankyo Deutschland GmbH
Germany (DE)
Università degli studi di Milano
Italy (IT)
Daiichi Sankyo USA, Inc.
United States (USA) (US)
Aichi Cancer Center Research Institute
Japan (JP)
Germany (DE)
Università degli studi di Milano
Italy (IT)
Daiichi Sankyo USA, Inc.
United States (USA) (US)
Aichi Cancer Center Research Institute
Japan (JP)
How to cite
APA:
Curigliano, G., Dunton, K., Rosenlund, M., Janek, M., Cathcart, J., Liu, Y.,... Iwata, H. (2022). Patient-reported outcomes (PROs) from DESTINY-Breast03, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC). In ANNALS OF ONCOLOGY (pp. S196-S197). AMSTERDAM: ELSEVIER.
MLA:
Curigliano, G., et al. "Patient-reported outcomes (PROs) from DESTINY-Breast03, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC)." Proceedings of the ANNALS OF ONCOLOGY AMSTERDAM: ELSEVIER, 2022. S196-S197.
BibTeX: Download